Loading...
Market
Will Recursion Pharmaceuticals ($RXRX) stock price exceed $20 by December 31, 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
NASDAQ stock market data
Story
Recursion Pharmaceuticals ($RXRX) Announces Positive Phase 2 Results for REC-994 in CCM
Sep 3, 2024, 12:08 PM
Recursion Pharmaceuticals ($RXRX) has announced positive Phase 2 topline results for REC-994, a first-in-disease investigational treatment for symptomatic cerebral cavernous malformation (CCM). The drug met its primary endpoint of safety and tolerability. Additionally, magnetic resonance imaging (MRI)-based secondary efficacy endpoints showed a trend towards reduced lesion volume. Despite these promising results, some investors remain cautious about the AI drug discovery developer's future prospects.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Below $2 billion • 25%
$2 billion to $4 billion • 25%
$4 billion to $6 billion • 25%
Above $6 billion • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
